Future Directions for Mantle Cell Lymphoma

Posted On 2021-03-03 16:40:41

This series on “Future Directions for Mantle Cell Lymphoma” is edited by Dr. Martin Dreyling, from Medizinische Klinik III der Universität München-Grosshadern, München, Germany.

Review Article on Future Directions for Mantle Cell Lymphoma
Mantle cell lymphoma pathology update in the 2016 WHO classification
Luis Veloza, Inmaculada Ribera-Cortada, Elias Campo

Risk stratification of mantle cell lymphoma (MCL)
Nora Liebers, Peter Dreger, Martin Dreyling, Sascha Dietrich

Minimal residual disease (MRD) in mantle cell lymphoma
Marco Ladetto, Rita Tavarozzi, Christiane Pott

Recent advances in the first-line treatment of mantle cell lymphoma
Morgane Cheminant, Martin Dreyling, Olivier Hermine

Front-line therapy in elderly patients with mantle cell lymphoma
Victor M. Orellana-Noia, Johanna C. Kluin-Nelemans, Michael E. Williams

Is there a role for immunomodulatory drugs in the treatment of mantle cell lymphoma?
Alexandra Albertsson-Lindblad, Mats Jerkeman

Venetoclax for the treatment of mantle cell lymphoma
Victor S. Lin, Mary Ann Anderson, David C. S. Huang, Andrew W. Roberts, John F. Seymour, Constantine S. L. Tam

Immunologic treatment strategies in mantle cell lymphoma: checkpoint inhibitors, chimeric antigen receptor (CAR) T-cells, and bispecific T-cell engager (BiTE) molecules
Joshua C. Pritchett, Stephen M. Ansell

Targeting CDK4/6 in mantle cell lymphoma
Christina Lee, Xiangao Huang, Maurizio Di Liberto, Peter Martin, Selina Chen-Kiang

Tailored treatment in mantle cell lymphoma
Simone Ferrero, Daniele Grimaldi, Martin Dreyling, on behalf of European Mantle Cell Lymphoma Network

The series “Future Directions for Mantle Cell Lymphoma” was commissioned by the editorial office, Annals of Lymphoma without any sponsorship or funding. Martin Dreyling served as the unpaid Guest Editor for the series.